Sevcar 800mg Tablet

Sevcar 800mg Tablet contains the active ingredient sevelamer carbonate, a phosphate binder used to control high phosphate levels in patients with chronic kidney disease (CKD) on dialysis. By binding to phosphate in the digestive tract, Sevcar prevents its absorption into the bloodstream, helping to maintain normal phosphate levels. Proper management of phosphate is crucial in CKD patients to reduce the risk of bone disease and vascular calcification, which are common complications of high phosphate levels.

Uses:

• Management of hyperphosphatemia (high phosphate levels) in patients with chronic kidney disease on dialysis.
• Prevention of bone disease and vascular calcification due to excess phosphate.

Side Effects:

• Common side effects: nausea, vomiting, diarrhea, constipation, and stomach pain.
• Serious side effects: gastrointestinal obstruction or perforation, which are rare but require immediate medical attention if symptoms like severe abdominal pain, bloating, or constipation occur.

Key Features:

• Contains sevelamer carbonate, a non-calcium, non-metal phosphate binder.
• Helps control high phosphate levels in CKD patients on dialysis.
• Reduces the risk of bone disease and vascular complications.
• Taken orally with meals to bind dietary phosphate effectively.

FAQ:

1. How does Sevcar 800mg Tablet work?
   Sevcar binds to phosphate in the intestines, preventing its absorption and helping to keep phosphate levels in a safe range for kidney disease patients.
2. Who should use Sevcar?
   Sevcar is prescribed for patients with chronic kidney disease on dialysis who have elevated phosphate levels. It is particularly useful for those at risk of calcium overload from other phosphate binders.
3. What precautions should I take while on Sevcar?
   Patients should take Sevcar with meals as directed and report any unusual digestive symptoms to their healthcare provider. Regular blood tests to monitor phosphate levels are also essential.

References:

1. Genzyme Corporation. “Renvela (sevelamer carbonate) tablets, for oral use.” U.S. Food and Drug Administration. [Accessed on 5 Nov 2024]. Available from: https://medlineplus.gov/druginfo/meds/a601248.html
2. European Medicines Agency (EMA). “Sevelamer carbonate (Sevcar) Product Information.” [Accessed on 5 Nov 2024]. Available from: https://www.ema.europa.eu/en/documents/product-information/renvela-epar-product-information_en.pdf